Use of Alternative Methodologies for Evaluation of Composite End Points in Trials of Therapies for Critical Limb Ischemia

Overview

Journal Am Heart J

Specialty Cardiology & Vascular Diseases

Date 2012 Sep 18

PMID 22980292

Citations 8

Authors

Sumeet Subherwal

Kevin J Anstrom

William S Jones

Michael G Felker

Sanjay Misra

Michael S Conte

William R Hiatt

Manesh R Patel

Affiliations

Soon will be listed here.

Citing Articles

Postoperative Pulmonary Complications' Association with Sugammadex versus Neostigmine: A Retrospective Registry Analysis.

Li G, Freundlich R, Gupta R, Hayhurst C, Le C, Martin B Anesthesiology. 2021; 134(6):862-873.

PMID: 33730169 PMC: 8114582. DOI: 10.1097/ALN.0000000000003735.

Overcoming underpowering: Trial simulations and a global rank end point to optimize clinical trials in children with heart disease.

Hill K, Baldwin H, Bichel D, Ellis A, Graham E, Hornik C Am Heart J. 2020; 226:188-197.

PMID: 32599259 PMC: 7442685. DOI: 10.1016/j.ahj.2020.05.011.

Win Ratio -An Intuitive and Easy-To-Interpret Composite Outcome in Medical Studies.

Wang H, Peng J, Zheng J, Wang B, Lu X, Chen C Shanghai Arch Psychiatry. 2017; 29(1):55-60.

PMID: 28769547 PMC: 5518256. DOI: 10.11919/j.issn.1002-0829.217011.

An optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.

Matsouaka R, Singhal A, Betensky R Stat Methods Med Res. 2016; 27(8):2384-2400.

PMID: 27920364 PMC: 5393279. DOI: 10.1177/0962280216680524.

Power and sample size calculations for the Wilcoxon-Mann-Whitney test in the presence of death-censored observations.

Matsouaka R, Betensky R Stat Med. 2014; 34(3):406-31.

PMID: 25393385 PMC: 4289456. DOI: 10.1002/sim.6355.

References

Finkelstein D, Schoenfeld D . Combining mortality and longitudinal measures in clinical trials. Stat Med. 1999; 18(11):1341-54. DOI: 10.1002/(sici)1097-0258(19990615)18:11<1341::aid-sim129>3.0.co;2-7. View

Felker G, Maisel A . A global rank end point for clinical trials in acute heart failure. Circ Heart Fail. 2010; 3(5):643-6. DOI: 10.1161/CIRCHEARTFAILURE.109.926030. View

Morishita R, Aoki M, Hashiya N, Makino H, Yamasaki K, Azuma J . Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension. 2004; 44(2):203-9. DOI: 10.1161/01.HYP.0000136394.08900.ed. View

Armstrong P, Westerhout C, Van de Werf F, Califf R, Welsh R, Wilcox R . Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. Am Heart J. 2011; 161(5):848-54. DOI: 10.1016/j.ahj.2010.12.026. View

Lim E, Brown A, Helmy A, Mussa S, Altman D . Composite outcomes in cardiovascular research: a survey of randomized trials. Ann Intern Med. 2008; 149(9):612-7. DOI: 10.7326/0003-4819-149-9-200811040-00004. View

Walter D, Krankenberg H, Balzer J, Kalka C, Baumgartner I, Schluter M . Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv. 2011; 4(1):26-37. DOI: 10.1161/CIRCINTERVENTIONS.110.958348. View

Pocock S, Ariti C, Collier T, Wang D . The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2011; 33(2):176-82. DOI: 10.1093/eurheartj/ehr352. View

Peters E, Childs M, Wunderlich R, Harkless L, Armstrong D, Lavery L . Functional status of persons with diabetes-related lower-extremity amputations. Diabetes Care. 2001; 24(10):1799-804. DOI: 10.2337/diacare.24.10.1799. View

Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi J . Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008; 358(7):689-99. DOI: 10.1056/NEJMoa0706356. View

10.

Grunkemeier G, Jin R, Starr A . Prosthetic heart valves: Objective Performance Criteria versus randomized clinical trial. Ann Thorac Surg. 2006; 82(3):776-80. DOI: 10.1016/j.athoracsur.2006.06.037. View

11.

Conte M, Geraghty P, Bradbury A, Hevelone N, Lipsitz S, Moneta G . Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg. 2009; 50(6):1462-73.e1-3. DOI: 10.1016/j.jvs.2009.09.044. View

12.

Kumar A, Brooks S, Cavanaugh K, Zuckerman B . FDA perspective on objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg. 2009; 50(6):1474-6. DOI: 10.1016/j.jvs.2009.09.045. View

13.

Parides M, Moskowitz A, Ascheim D, Rose E, Gelijns A . Progress versus precision: challenges in clinical trial design for left ventricular assist devices. Ann Thorac Surg. 2006; 82(3):1140-6. DOI: 10.1016/j.athoracsur.2006.05.123. View

14.

Lachin J . Worst-rank score analysis with informatively missing observations in clinical trials. Control Clin Trials. 1999; 20(5):408-22. DOI: 10.1016/s0197-2456(99)00022-7. View

15.

Brass E, Lewis R, Lipicky R, Murphy J, Hiatt W . Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk. Clin Pharmacol Ther. 2006; 79(3):165-72. DOI: 10.1016/j.clpt.2005.11.012. View

16.

Brass E, Anthony R, Dormandy J, Hiatt W, Jiao J, Nakanishi A . Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg. 2006; 43(4):752-9. DOI: 10.1016/j.jvs.2005.11.041. View

17.

Tang Y . Size and power estimation for the Wilcoxon-Mann-Whitney test for ordered categorical data. Stat Med. 2011; 30(29):3461-70. DOI: 10.1002/sim.4407. View

18.

Felker G, Anstrom K, Rogers J . A global ranking approach to end points in trials of mechanical circulatory support devices. J Card Fail. 2008; 14(5):368-72. DOI: 10.1016/j.cardfail.2008.01.009. View

19.

Jones W, Annex B . Growth factors for therapeutic angiogenesis in peripheral arterial disease. Curr Opin Cardiol. 2007; 22(5):458-63. DOI: 10.1097/HCO.0b013e328236741b. View

20.

Belch J, Hiatt W, Baumgartner I, Driver I, Nikol S, Norgren L . Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet. 2011; 377(9781):1929-37. DOI: 10.1016/S0140-6736(11)60394-2. View